Alcohol-Associated Hepatitis

Alcohol-associated hepatitis (AH) is an acute inflammatory syndrome within alcohol-associated liver disease that typically presents with recent jaundice after sustained heavy alcohol use. It matters clinically because severe AH carries high short-term mortality, is frequently complicated by infection, kidney injury, encephalopathy, and acute-on-chronic liver failure, and requires rapid guideline-based diagnosis, severity assessment, supportive care, corticosteroid decisions, and transplant consideration (Jophlin et al., 2024; EASL, 2018).

Learning objectives

Diagnose probable AH using the NIAAA clinical criteria and recognize when liver biopsy is needed.
Perform a focused inpatient workup including history, physical exam, labs, paracentesis, and imaging while excluding competing causes.
Use MELD as the preferred contemporary severity score, understand the historical role of Maddrey discriminant function (mDF), and apply the Lille score after steroid initiation.
Deliver guideline-based management including nutrition, alcohol use disorder treatment, complication management, corticosteroids, and transplant referral when appropriate.
Counsel patients on prognosis using specific survival data for moderate vs severe AH, steroid response vs nonresponse, abstinence, and early liver transplantation.

Definition and brief pathophysiology

AH is a clinical syndrome of acute hepatic inflammation caused by sustained heavy alcohol exposure, often superimposed on steatosis, fibrosis, or cirrhosis.
Key mechanisms:
- ethanol metabolism generates acetaldehyde, oxidative stress, and mitochondrial injury
- gut barrier dysfunction increases endotoxin exposure
- Kupffer-cell activation and cytokine signaling drive neutrophil-rich inflammation
- cholestasis, hepatocyte ballooning, and impaired regeneration worsen jaundice and organ failure (Jophlin et al., 2024; EASL, 2018).

Diagnosis

Suspect AH in a patient with recent heavy alcohol use and new or worsening jaundice.
Supportive findings include fever, tender hepatomegaly, leukocytosis, ascites, encephalopathy, and SIRS.
Probable AH (NIAAA clinical criteria):
- onset of jaundice within the previous 8 weeks
- ongoing alcohol use of >40 g/day in women or >60 g/day in men for ≥6 months
- <60 days of abstinence before jaundice onset
- total bilirubin >3 mg/dL
- AST >50 U/L
- AST:ALT >1.5
- both AST and ALT typically <400 U/L
- no more likely competing cause of acute hepatitis (Crabb et al., 2016; Jophlin et al., 2024)
AH is primarily a clinical diagnosis.

When should liver biopsy be strongly considered?

Uncertain alcohol exposure history
Atypical AST/ALT pattern
Concern for drug-induced liver injury, ischemic hepatitis, autoimmune hepatitis, viral hepatitis, biliary obstruction/cholangitis, Wilson disease, Budd-Chiari syndrome, portal vein thrombosis, or malignant infiltration
When confirmation would change corticosteroid use, trial eligibility, or transplant decision-making

Guideline-based workup

History

Quantity, pattern, and recency of alcohol use; last drink; prior withdrawal
Prior liver decompensation, prior AH, pancreatitis, GI bleeding
Medications, supplements, acetaminophen, herbal agents, other substances
Infectious symptoms, abdominal pain, diarrhea, melena, hematemesis, confusion
Nutrition, weight loss, frailty, social support, prior AUD treatment

Physical exam

Jaundice, hepatomegaly, ascites, edema, asterixis, encephalopathy
Fever, SIRS, volume status, bleeding, stigmata of chronic liver disease
Evaluate for alcohol withdrawal and hepatic encephalopathy, which may coexist

Laboratory evaluation

CBC, CMP, bilirubin, AST/ALT, alkaline phosphatase
INR/PT, albumin, creatinine, glucose
Viral hepatitis testing
Blood and urine cultures when indicated
Diagnostic paracentesis for new or worsening ascites

Imaging

RUQ ultrasound with Doppler is first-line
Assess for cirrhosis, steatosis, ascites, biliary dilation, portal/hepatic vein thrombosis
CT or MRI selectively for pancreatitis, malignancy, abscess, or uncertain obstruction (Jophlin et al., 2024; EASL, 2018).

Differential diagnosis

Acute viral hepatitis
Drug-induced liver injury
Ischemic hepatitis
Autoimmune hepatitis
Acute biliary obstruction or cholangitis
Wilson disease in younger patients
Budd-Chiari syndrome
Portal vein thrombosis
Sepsis-associated cholestasis
Decompensated cirrhosis without superimposed AH
Hepatocellular carcinoma or other malignant infiltration

Severity assessment

MELD is the preferred current score in guideline-based practice.
- Moderate AH: MELD ≤20
- Severe AH: MELD >20
ACG recommends using MELD >20 to stratify severity, estimate short-term mortality risk, and guide corticosteroid use (Jophlin et al., 2024).

Maddrey discriminant function (mDF)

Formula: 4.6 × (patient PT − control PT) + bilirubin (mg/dL)
mDF is the historical severity score used in classic AH trials.
mDF ≥32 defines severe disease in the historical literature and predicts about 20% to 50% 30-day mortality (Jophlin et al., 2024).
Current guidelines favor MELD over mDF because MELD has better prognostic performance, uses INR rather than local PT calibration, and incorporates creatinine (Morales-Arráez et al., 2022; Jophlin et al., 2024).

When are steroids recommended?

Current ACG approach: recommend corticosteroids for severe AH defined by MELD >20, if there are no contraindications (Jophlin et al., 2024).
Historical approach: corticosteroids were typically studied in patients with mDF ≥32, and many classic trials enrolled patients using that threshold (Maddrey et al., 1978).
Practical interpretation:
- use MELD as the preferred decision framework now
- use mDF mainly to interpret older evidence and older bedside terminology

Prognosis and survival data

Severe AH
- contemporary guidance cites 1-month mortality of 20% to 50% (Jophlin et al., 2024)
- current cohorts report 90-day survival ranging from 35% to 70%, depending on severity and treatment response (Jophlin et al., 2024)
Moderate AH
- 1-year mortality ranges from 10% to 20% (Jophlin et al., 2024)
If severe AH is evaluated for transplant but early transplant is not performed
- among the 95 nontransplanted patients in one LT-evaluation cohort, spontaneous recovery by day 90 occurred in 34/95 (35.8%)
- only 7/95 (7.4%) achieved a compensated state by the end of follow-up; this was 20.6% of those with spontaneous recovery (Musto et al., 2022)
Abstinence improves survival
- complete abstinence after an episode of AH was associated with better long-term survival (HR 0.53, p=0.03) (Altamirano et al., 2017)
Early transplant in selected severe nonresponders
- markedly improves short-term survival and can provide excellent longer-term outcomes in carefully selected patients (Mathurin et al., 2011; Lee et al., 2018)

Complications

Infection and sepsis
Acute kidney injury and hepatorenal syndrome
Hepatic encephalopathy
Ascites and spontaneous bacterial peritonitis
Variceal bleeding
Acute-on-chronic liver failure
Severe malnutrition and micronutrient deficiency
Alcohol withdrawal syndrome (Jophlin et al., 2024).

Inpatient surveillance priorities

Daily mental status, volume status, and infection reassessment
Serial bilirubin, creatinine, INR, sodium, CBC
Low threshold for cultures and repeat paracentesis
Monitor for bleeding, aspiration, withdrawal, poor intake, and worsening organ failure

Management: core guideline-based care

Hospitalize severe AH, especially if there is encephalopathy, AKI, infection, GI bleeding, or ACLF (Jophlin et al., 2024).
Treat the whole syndrome:
- search for infection aggressively
- manage bleeding, ascites, encephalopathy, AKI/HRS, and alcohol withdrawal
- involve hepatology, addiction medicine, nutrition, and social work early
Nutrition is core therapy
- target 35 kcal/kg/day
- target 1.2 to 1.5 g/kg/day protein
- if intake is <21 kcal/kg/day, add oral supplementation and consider enteral feeding
- replete thiamine, vitamin B12, and zinc (Jophlin et al., 2024)
Alcohol use disorder treatment is essential
- relapse prevention should begin during hospitalization
- sustained abstinence is one of the strongest determinants of survival (Altamirano et al., 2017; Jophlin et al., 2024)

Common pitfalls in initial management

Starting steroids before excluding uncontrolled infection or major competing diagnoses
Underfeeding the patient
Missing alcohol withdrawal because encephalopathy is also present
Continuing steroids despite clear nonresponse
Treating the liver while failing to start an AUD treatment plan

Corticosteroids

ACG recommendation: in severe AH (MELD >20), treat with corticosteroids if there are no contraindications (Jophlin et al., 2024).
Standard regimen:
- prednisolone 40 mg daily for 4 weeks
- prednisone 40 mg daily for 4 weeks may be used if prednisolone is unavailable
- IV methylprednisolone 32 mg/day if oral therapy is not feasible
- there is no evidence that rapid vs slow tapering after the 4-week course improves outcomes (Jophlin et al., 2024)
Reassess with Lille score at day 4 or day 7
Stop corticosteroids if Lille >0.45 (Garcia-Saenz-de-Sicilia et al., 2017; Jophlin et al., 2024)
The maximum short-term benefit appears in patients with MELD 25 to 39; benefit is more limited in the 40 to 50 range and absent above MELD >51 (Arab et al., 2021; Jophlin et al., 2024).

Contraindications or reasons to defer steroids

Uncontrolled infection or sepsis
Active GI bleeding
Severe renal failure or rapidly progressive multiorgan failure
Uncontrolled diabetes or marked hyperglycemia
Untreated hepatitis B or another major competing infection
Significant diagnostic uncertainty where steroids may be harmful
Note: after adequate control of infection, GI bleeding, or renal failure, corticosteroids may still be reconsidered in selected patients (Jophlin et al., 2024).

Adjunctive and nonrecommended therapies

IV N-acetylcysteine (NAC) may be used as an adjunct to corticosteroids in severe AH.
ACG highlights a 5-day IV NAC course as the main adjunctive option (Jophlin et al., 2024).
Do not use pentoxifylline routinely (Jophlin et al., 2024).
Do not use universal prophylactic antibiotics; treat documented infection, but routine prophylaxis has not improved survival (Jophlin et al., 2024).
Anti-TNF biologics are not recommended because of infection risk and harm.

Early liver transplantation

Early liver transplantation should be considered in highly selected patients with severe AH who:
- do not respond to medical therapy
- cannot receive corticosteroids
- have acceptable psychosocial and addiction-risk assessment
Modern guidance emphasizes careful candidate selection, not a rigid sobriety cutoff alone (Jophlin et al., 2024).

Palliative care and escalation

Consider ICU-level escalation for worsening encephalopathy, shock, respiratory failure, severe AKI, or ACLF.
In severe AH with 4 or more organ failures, steroid nonresponse, and no early transplant option, ACG notes that palliative therapy is appropriate (Jophlin et al., 2024).
Palliative care can run in parallel with active hepatology care for symptom management, goals-of-care discussions, and family support.

When urgent escalation is needed

Rising MELD, creatinine, or bilirubin despite therapy
Lille nonresponse after steroid trial
Recurrent or uncontrolled infection
Progressive ACLF or multiorgan failure
Inability to maintain nutrition
Persistent encephalopathy or refractory ascites

Key clinical pearls

Diagnose AH clinically first; biopsy is reserved for uncertainty.
Use MELD as the preferred current severity score.
Recognize mDF ≥32 as the classic threshold for severe disease and historical steroid eligibility.
In current practice, corticosteroids are recommended mainly for MELD >20 if there are no contraindications.
Reassess with Lille score at day 4 or day 7 and stop steroids if Lille >0.45.
Nutrition, vitamin repletion, infection surveillance, and AUD treatment are core therapy, not add-ons.
Early transplant review should be considered in selected severe nonresponders.

References

Jophlin et al., 2024 — ACG Clinical Guideline: Alcohol-Associated Liver Disease.
EASL, 2018 — EASL Clinical Practice Guidelines: Management of alcohol-related liver disease.
Crabb et al., 2016 — Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia.
Maddrey et al., 1978 — Corticosteroid Therapy of Alcoholic Hepatitis.
Morales-Arráez et al., 2022 — The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study.
Garcia-Saenz-de-Sicilia et al., 2017 — A Day-4 Lille Model Predicts Response to Corticosteroids and Mortality in Severe Alcoholic Hepatitis.
Mathurin et al., 2011 — Corticosteroids Improve Short-Term Survival in Patients With Severe Alcoholic Hepatitis: Meta-analysis of Individual Patient Data.
Thursz et al., 2015 — Prednisolone or Pentoxifylline for Alcoholic Hepatitis.
Louvet et al., 2018 — Corticosteroids Reduce Risk of Death Within 28 Days for Patients With Severe Alcoholic Hepatitis, Compared With Pentoxifylline or Placebo.
Arab et al., 2021 — Identification of Optimal Therapeutic Window for Steroid Use in Severe Alcohol-Associated Hepatitis: A Worldwide Study.
Nguyen-Khac et al., 2011 — Glucocorticoids Plus N-Acetylcysteine in Severe Alcoholic Hepatitis.
Louvet et al., 2023 — Effect of Prophylactic Antibiotics on Mortality in Severe Alcohol-Related Hepatitis: A Randomized Clinical Trial.
Mathurin et al., 2011 — Early Liver Transplantation for Severe Alcoholic Hepatitis.
Lee et al., 2018 — Outcomes of Early Liver Transplantation for Patients With Severe Alcoholic Hepatitis.
Altamirano et al., 2017 — Alcohol Abstinence in Patients Surviving an Episode of Alcoholic Hepatitis: Prediction and Impact on Long-Term Survival.
Musto et al., 2022 — Recovery and Outcomes of Patients Denied Early Liver Transplantation for Severe Alcohol-Associated Hepatitis.